Description

Alnylam Pharmaceuticals’ $1 Billion AMVUTTRA Quarter — Is A New Biotech Powerhouse Emerging?

Alnylam Pharmaceuticals reported strong performance in the second quarter of 2026, marked by significant revenue growth driven primarily by its AMVUTTRA product for ATTR cardiomyopathy. This quarter represents a milestone as AMVUTTRA revenues exceeded $1 billion for the first time in a single quarter, reflecting an annualized run rate above $4 billion. The growth is largely attributed to the successful commercial launch, broad market access, and expanding provider adoption, particularly in the first-line treatment setting, which now accounts for approximately 80% of new patient starts. Geographic expansion strategies also advanced with a new collaboration announced to commercialize AMVUTTRA in Mainland China and Macau, subject to regulatory approval. Despite the positive momentum, Alnylam lowered its 2026 total net product revenue guidance by $200 million at the midpoint, mainly due to a reassessment of second-line demand normalization following an initial surge driven by pent-up patient demand for a new therapy.